Richard Pops Sells 15,000 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) Director Richard Pops sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the sale, the director owned 34,480 shares in the company, valued at approximately $5,435,772. This trade represents a 30.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $154.36 on Wednesday. Neurocrine Biosciences, Inc. has a 1 year low of $117.59 and a 1 year high of $162.39. The firm’s 50 day moving average price is $135.12 and its 200 day moving average price is $138.57. The firm has a market cap of $15.52 billion, a P/E ratio of 23.78, a price-to-earnings-growth ratio of 1.18 and a beta of 0.34.

Get Neurocrine Biosciences alerts:

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in Neurocrine Biosciences during the 4th quarter worth $25,000. Golden State Wealth Management LLC increased its stake in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares during the period. DJE Kapital AG purchased a new stake in Neurocrine Biosciences during the 4th quarter worth $28,000. Geneos Wealth Management Inc. increased its stake in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. Finally, Quent Capital LLC purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth $32,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NBIX. Truist Financial lifted their price target on shares of Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Leerink Partners lifted their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Zacks Research upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Wolfe Research began coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price target on the stock. Finally, UBS Group decreased their price target on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $184.15.

Check Out Our Latest Stock Analysis on NBIX

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

Featured Stories

• Five stocks we like better than Neurocrine Biosciences
• HIVE Weaponizes Power for an AI Pivot
• A Deep Dive Into NVIDIA’s Latest Portfolio Moves
• Brady Corp Wires Up a Massive AI-Powered Breakout
• Why Home Depot’s Sell-Off Could Become a Huge Opportunity

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.